D-Glutamate

D-Glutamate

SCHEMBL1444865

CC(N)C(=O)O.NC(CCC(=O)O)C(=O)O

nearest known ligand 0.82

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.82
GRM8 O00222 2/20 0.82
GRM6 O15303 2/20 0.82
GRM7 Q14831 2/20 0.82
GRM4 Q14833 2/20 0.82
GRIN2D O15399 1/20 0.82
GRIN3B O60391 1/20 0.82
GSR P00390 1/20 0.82
GRIK1 P39086 1/20 0.82
GRM5 P41594 1/20 0.82
GRIA1 P42261 1/20 0.82
GRIA2 P42262 1/20 0.82
GRIA3 P42263 1/20 0.82
SLC1A3 P43003 1/20 0.82
SLC1A2 P43004 1/20 0.82
SLC1A1 P43005 1/20 0.82
GRIA4 P48058 1/20 0.82
GRIN1 Q05586 1/20 0.82
GRIN2A Q12879 1/20 0.82
GRIK2 Q13002 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glutamic Acid SCHEMBL29406755 1.00 CYP1A2 (0.82) CYP1A2GRM8GRM6GRM7GRM4
Glutamic Acid SCHEMBL4531318 1.00 CYP1A2 (0.82) CYP1A2GRM8GRM6GRM7GRM4
D-Glutamate SCHEMBL8637356 1.00 CYP1A2 (0.82) CYP1A2GRM8GRM6GRM7GRM4
Glutamic Acid SCHEMBL1444866 1.00 CYP1A2 (0.82) CYP1A2GRM8GRM6GRM7GRM4
D-Glutamate SCHEMBL4531315 1.00 CYP1A2 (0.82) CYP1A2GRM8GRM6GRM7GRM4
Glutamic Acid SCHEMBL16241513 0.98 CYP1A2 (0.78) CYP1A2GRM8GRM6GRM7GRM4
Glutamic Acid SCHEMBL9679295 0.94 CYP1A2 (0.72) CYP1A2GRM8GRM6GRM7GRM4
Glutamic Acid SCHEMBL1963375 0.94 CYP1A2 (0.72) CYP1A2GRM8GRM6GRM7GRM4
D-Glutamate SCHEMBL9679290 0.94 CYP1A2 (0.72) CYP1A2GRM8GRM6GRM7GRM4
D-Glutamate SCHEMBL1963374 0.94 CYP1A2 (0.72) CYP1A2GRM8GRM6GRM7GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118201943-A Anti-inflammatory compound and application thereof 映恩生物制药(苏州)有限公司 2024-06-14 CN claimed
CN-118005762-A Polypeptide ligand of targeted scavenger receptor, non-covalent double-targeted molecule and pharmaceutical application thereof 北京大学 2024-05-10 CN claimed
CN-116670120-A Process for preparing carboxylic cyclic anhydride 北京大学 2023-08-29 CN claimed
CN-111296114-B Maintenance method for landscaping 华绿建设有限公司 2023-03-28 CN claimed
CN-111657273-B Nano-silver bactericidal composition for fresh flowers 福建省农通科技发展有限公司 2022-08-09 CN claimed
CN-114634460-A Process for preparing carboxyanhydrides 北京大学 2022-06-17 CN claimed
CN-111657273-A Nano-silver bactericidal composition for fresh flowers 福建省凡通科技发展有限公司 2020-09-15 CN claimed
CN-111296222-A Transplanting process for big trees 华绿建设有限公司 2020-06-19 CN claimed
CN-111296114-A Maintenance method for landscaping 华绿建设有限公司 2020-06-19 CN claimed
CN-108514529-A A kind of extracting method and application thereof of skin-lightening cosmetic Chinese medical extract 张言聚 2018-09-11 CN claimed
CN-108103039-A One group of fucosyltransferase mutant and its screening technique and application 上海交通大学 2018-06-01 CN claimed
CN-102245208-B immunoglobulin variants and uses thereof HOFFMAN-LA ROCHE LTD. (CH) 2016-03-16 CN claimed
JP-55043140-A None JP disclosed
US-12442027-B2 Method of reducing aromatic nitro compounds AMGEN INC. (US) 2025-10-14 US disclosed
US-12162816-B2 Method of reducing aromatic nitro compounds JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2024-12-10 US disclosed
EP-4464307-A1 COSMETIC COMPOSITION AND METHODS OF MAKING THE SAME MPLUS COSMETICS S.R.L. (IT) 2024-11-20 EP disclosed
CN-1310025-A Therapeutical compound and its application AMERICAN FINNIE BIO SCIENCE IN (US) 2001-08-29 CN disclosed
EP-0298641-A2 Acid urease and production thereof Takeda Chemical Industries, Ltd. (JP) 1989-01-11 EP disclosed
US-4342827-A GLYCEROL DEHYDROGENASE ENZYMES PRODUCED FROM BACILLUS STEAROTHERMOPHILUS PUBLIC HEALTH LABORATORY SERVICE, CENTER FOR APPLIED MICROBIOLOGY & RESEARCH (GB) 1982-08-03 US disclosed
JP-S5543140-A AEROSOL PREPARATION NISSHIN KAGAKU KK 1980-03-26 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12442027-B2 Method of reducing aromatic nitro compounds NNMT, CBR3, DHFR CYP1A2 25/4885GRM8 3708/4885GRM6 2815/4885
US-12162816-B2 Method of reducing aromatic nitro compounds TYR, COMT, TH CYP1A2 160/4885GRM8 3161/4885GRM6 3403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.